CRISPR Therapeutics Q3 CASGEVY Revenue Jumps 30% Sequentially
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…
Story updates
09:14:01 PM UTC
SquawkNews
CRISPR Therapeutics reported third-quarter 2026 revenue of $12.7 million and a net loss of $111.4 million. Collaboration revenue was $12.3 million, while cash, cash equivalents and marketable securities totaled $2.28 billion at quarter-end. The company also reported progress across CASGEVY and its…
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…